



bjc@springernature.com <bjc@springernature.com>

Thu 9/1/2022 8:22 AM

To: Fidelman, Nicholas <Nicholas.Fidelman@ucsf.edu>

This Message Is From an External Sender

This message came from outside your organization.

Dear Dr Fidelman,

Manuscript: BJC-A3341901

Title: Phase I Prospective Trial of TAS-102 (trifluridine and tipiracil) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Authors: Nicholas Fidelman, Chloe Atreya, Madeline Griffith, Marion Milloy, Julia Carnevale, Pelin Cinar, Alan Venook, and Katherine Van Loon

In recent years the number of manuscripts submitted to the *British Journal of Cancer* has increased considerably and our rejection rate has risen. Many of these manuscripts are rejected without formal review if the subject editor considers that they are unlikely to be of interest to the majority of readers of the journal. As subject editor, I have assessed your manuscript and I regret to inform you that it is unlikely to be of sufficient priority for publication in the *British Journal of Cancer*.

Alternatively, I think your article could be well-suited to readers at BMC Cancer. This fully Open Access journal is BMC's largest oncology journal; it publishes leading research in molecular, translational and clinical oncology.

If you wish to submit your article for priority consideration at BMC Cancer, please send this decision letter along with your full manuscript file to the [Editor of BMC Cancer](#), who would be happy to discuss your submission and ensure it is prioritised for consideration.

You may instead [directly submit your article to BMC Cancer. If you choose this option, please save this email as a PDF or MSG file and upload it with your submission as a supplementary file entitled 'Transfer Letter British Journal of Cancer'.

I am sorry that I am unable to accept your article into the *British Journal of Cancer* on this occasion, and hope that we will have the opportunity to consider further submissions from you in the future.

Yours sincerely,

Professor Jeff Evans
Clinical Subject Editor
British Journal of Cancer
BJC Editorial Office
University of Glasgow
Institute of Cancer Sciences
Wolfson Wohl TCRC
Garscube Estate
GLASGOW G61 1QH
Tel: +44 (0)141 330 5315
Fax: +44 (0)141 330 4127
E-mail: bjc@springernature.com

This email has been sent through the NPG Manuscript Tracking System NY-610A-NPG&MTS

Confidentiality Statement:

This e-mail is confidential and subject to copyright. Any unauthorised use or disclosure of its contents is prohibited. If you have received this email in error please notify our Manuscript Tracking System Helpdesk team at <http://platformsupport.nature.com> .

Details of the confidentiality and pre-publicity policy may be found here <http://www.nature.com/authors/policies/confidentiality.html>

[Privacy Policy](#) | [Update Profile](#)